Advocacy intelligence hub — real-time data for patient organizations
Fresenius Kabi
Fresenius Kabi — PHASE4
Omegaven: FDA approved
Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Omegaven
Fresenius Kabi USA, LLC
Omegaven
(fish oil triglycerides)Orphan drugFresenius Kabi USA, LLC
12.1 Mechanism of Action Omegaven provides a biologically utilizable source of calories and essential fatty acids. Fatty acids serve as an important s...
Browse all Parenteral nutrition-associated cholestasis news →
Chief Scientific Operations Officer
Protara Therapeutics
Kunal Gupta, MD
University of Rochester
Meghan A Arnold, MD
University of Michigan
Andreas Repa, MD
Medical University Vienna
Nadja Haiden, MD
Medical University Vienna
Sanjiv Amin, MD, MD
University of Rochester
📍 ROCHESTER, NY
View all Parenteral nutrition-associated cholestasis specialists →